Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: A crucial role for Krüppel-like factor 2

Atherosclerosis

Volumn 214, Issue 2, 2011, Pages 345-349

  Van Tits, L J H ^a   Stienstra, R ^a   van Lent, P L ^b   Netea, M G ^a   Joosten, L A B ^a   Stalenhoef, A F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Gene expression; Kr ppel like factor 2; Macrophages differentiation; Oxidized LDL accumulation

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; KRUPPEL LIKE FACTOR 2; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; DOWN REGULATION; ENDOTHELIUM CELL; FOAM CELL; INFLAMMATION; MACROPHAGE; MONOCYTE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; STIMULATION;

ATHEROSCLEROSIS; CELLS, CULTURED; CHEMOKINE CCL2; CYTOKINES; FOAM CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; MACROPHAGE ACTIVATION; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; PHENOTYPE; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION;

EID: 79151484549     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.018     Document Type: Article

References (25)

1. Goerdt S., Politz O., Schledzewski K., et al. Alternative versus classical activation of macrophages. Pathobiology 1999, 67:222-226.
2. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
3. Mantovani A., Garlanda C., Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009, 29:1419-1423.
4. Goerdt S., Orfanos C.E. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 1999, 10:137-142.
5. Mantovani A., Locati M., Vecchi A., Sozzani S., Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001, 22:328-336.
6. Peiser L., Gordon S. The function of scavenger receptors expressed by macrophages and their role in the regulation of inflammation. Microbes Infect 2001, 3:149-159.
7. Ohlsson B.G., Englund M.C., Karlsson A.L., et al. Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-kappaB to DNA and the subsequent expression of tumor necrosis factor-alpha and interleukin-1beta in macrophages. J Clin Invest 1996, 98:78-89.
8. Mikita T., Porter G., Lawn R.M., Shiffman D. Oxidized low density lipoprotein exposure alters the transcriptional response of macrophages to inflammatory stimulus. J Biol Chem 2001, 276:45729-45739.
9. Groeneweg M., Kanters E., Vergouwe M.N., et al. Lipopolysaccharide-induced gene expression in murine macrophages is enhanced by prior exposure to oxLDL. J Lipid Res 2006, 47:2259-2267.
10. Waldo S.W., Li Y., Buono C., et al. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008, 172:1112-1126.
11. Kunjathoor V.V., Febbraio M., Podrez E.A., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002, 277:49982-49988.
12. Miller Y.I., Chang M.K., Binder C.J., Shaw P.X., Witztum J.L. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol 2003, 14:437-445.
13. Zhao B., Li Y., Buono C., et al. Constitutive receptor-independent low density lipoprotein uptake and cholesterol accumulation by macrophages differentiated from human monocytes with macrophage-colony-stimulating factor (M-CSF). J Biol Chem 2006, 281:15757-15762.
14. Dekker R.J., van S.S., Fontijn R.D., et al. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kruppel-like factor (KLF2). Blood 2002, 100:1689-1698.
15. Fledderus J.O., van Thienen J.V., Boon R.A., et al. Prolonged shear stress and KLF2 suppress constitutive proinflammatory transcription through inhibition of ATF2. Blood 2007, 109:4249-4257.
16. Kuo C.T., Veselits M.L., Leiden J.M. LKLF: a transcriptional regulator of single-positive T cell quiescence and survival. Science 1997, 277:1986-1990.
17. Das H., Kumar A., Lin Z., et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci USA 2006, 103:6653-6658.
18. Tuomisto T.T., Lumivuori H., Kansanen E., et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc Res 2008, 78:175-184.
19. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
20. Gu L., Okada Y., Clinton S.K., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998, 2:275-281.
21. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev 2004, 18:2195-2224.
22. Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997, 9:240-246.
23. Bouhlel M.A., Derudas B., Rigamonti E., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007, 6:137-143.
24. Jandeleit-Dahm K.A., Calkin A., Tikellis C., Thomas M. Direct antiatherosclerotic effects of PPAR agonists. Curr Opin Lipidol 2009, 20:24-29.
25. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.